Mayne Pharma has acquired on-market dermatology portfolio Foam Assets from GSK for $50.1m.

The Foam Assets includes US rights to Fabior and Sorilux, Canadian rights to Luxiq and Olux-E and Mexican rights to betamethasone foam.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

As per the deal, Mayne Pharma will secure the approved regulatory filings, trademarks, marketing materials, select product inventory, related medical and technical data and obtain licenses for related patents.

Fabior (tazarotene) Foam, 0.1% is a topical product for the treatment of acne, which affects up to 50 million Americans every year.

“The Foam Assets includes US rights to Fabior and Sorilux, Canadian rights to Luxiq and Olux-E and Mexican rights to betamethasone foam.”

Sorilux (calcipotriene) Foam, 0.005% is a topical product meant for mild-to-moderate plaque psoriasis, impacting up to 6 million Americans every year.

Mayne Pharma’s specialist brands division and existing sales team will market Fabior and Sorilux.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Both products will be relaunched next fiscal year and until then, GSK will continue to distribute Fabior and Sorilux as per a transition services arrangement.

GSK will continue to distribute the non-US dermatology assets in the short term.

Mayne Pharma plans to out-license these products to new partners.